ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,250.50
0.60%
S&P ASX All Technology
3,828.50
0.37%
Brent Oil
76.495
0.00%
US Dollar vs AUD
1.60849
0.00%
Bitcoin
98,277.03
0.07%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE

  6. Selvita Sa (0RKT) Share Price

Selvita Sa

Selvita Sa (0RKT)

LSE
57.00
0.00
(0.00%)
Closed 05 January 3:30AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
57.00
Bid
0.00
Offer
0.00
Volume
0.00
0.00 Day's Range 0.00
57.00 52 Week Range 57.00
Market Cap
1.318B
Previous Close
57.00
Open
-
Last Trade
(O)
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
1
Shares Outstanding
23,120,000
Dividend Yield
-
PE Ratio
-14.31
Earnings Per Share (EPS)
-3.98
Revenue
67.99M
Net Profit
-92.11M

About Selvita Sa

Sector
Chemicals & Chem Preps, Nec
Industry
Chemicals & Chem Preps, Nec
Website
ryvu.com
Headquarters
Krakow, Pol
Founded
-
Selvita Sa is listed in the Chemicals & Chem Preps sector of the London Stock Exchange with ticker 0RKT. The last closing price for Selvita was PLN57. Over the last year, Selvita shares have traded in a share price range of PLN 57.00 to PLN 57.00.

Selvita currently has 23,120,000 shares in issue. The market capitalisation of Selvita is PLN1.32 billion. Selvita has a price to earnings ratio (PE ratio) of -14.31.

Ask ADVFN Intelligence (AI)

0RKT Latest News

More News

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium PR Newswire KRAKOW, Poland, Oct. 23, 2024...

23 October 2024
PR Newswire (US)

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium PR Newswire KRAKOW, Poland, Oct. 9, 2024...

09 October 2024
PR Newswire (US)

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit PR Newswire KRAKOW, Poland, Sept. 23, 2024 ONCO Prime is a cutting-edge drug discovery...

24 September 2024
PR Newswire (US)

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress PR Newswire KRAKOW, Poland, June 14, 2024 RVU120 as a single agent showed...

15 June 2024
PR Newswire (US)

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting PR Newswire KRAKOW, Poland, March 6, 2024 Updated preclinical data will be...

06 March 2024
UK Regulatory

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS PR Newswire KRAKOW...

15 February 2024
UK Regulatory

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting PR Newswire KRAKOW, Poland, Nov. 2, 2023 Updated data from the Phase I trial of RVU120...

03 November 2023
PR Newswire (US)

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update PR Newswire KRAKOW, Poland, Sept. 28, 2022 KRAKOW, Poland, Sept. 28, 2022 /PRNewswire/ -- Ryvu...

29 September 2022
PR Newswire (US)

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress PR Newswire KRAKOW, Poland, June 10, 2022 - Clinically...

10 June 2022
PR Newswire (US)

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting PR Newswire KRAKOW, Poland, March 8, 2022 KRAKOW, Poland, March 8, 2022 /PRNewswire/ -- Ryvu Therapeutics...

09 March 2022
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10057575700DE
400575757457DE
1200575757157DE
2600575757157DE
5200575757057DE
15600575757057DE
26000575757057DE

0RKT - Frequently Asked Questions (FAQ)

What is the current Selvita share price?
The current share price of Selvita is PLN 57.00
How many Selvita shares are in issue?
Selvita has 23,120,000 shares in issue
What is the market cap of Selvita?
The market capitalisation of Selvita is PLN 1.32B
What is the 1 year trading range for Selvita share price?
Selvita has traded in the range of PLN 57.00 to PLN 57.00 during the past year
What is the PE ratio of Selvita?
The price to earnings ratio of Selvita is -14.31
What is the cash to sales ratio of Selvita?
The cash to sales ratio of Selvita is 19.38
What is the reporting currency for Selvita?
Selvita reports financial results in PLN
What is the latest annual turnover for Selvita?
The latest annual turnover of Selvita is PLN 67.99M
What is the latest annual profit for Selvita?
The latest annual profit of Selvita is PLN -92.11M
What is the registered address of Selvita?
The registered address for Selvita is ST. LEONA HENRYKA STERNBACHA 2, KRAKOW, 30-394
What is the Selvita website address?
The website address for Selvita is ryvu.com
Which industry sector does Selvita operate in?
Selvita operates in the CHEMICALS & CHEM PREPS, NEC sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TCFTheracryf Plc
0.725p
(38.10%)
7.56M
NMTNeometals Ltd
3.50p
(27.27%)
346.81k
SCHOScholium Group Plc
44.00p
(25.71%)
30.65k
FABFusion Antibodies Plc
10.15p
(24.54%)
3.34M
PYXPyx Resources Limited
3.49p
(22.24%)
8.43k
TM1Technology Minerals Plc
0.125p
(-24.24%)
37.21M
QUIZQuiz Plc
0.70p
(-18.60%)
3.67M
SYMESupply@me Capital Plc
0.003p
(-17.81%)
168.35M
OBDOxford Biodynamics Plc
1.20p
(-14.29%)
827.83k
ZENZenith Energy Ltd.
5.25p
(-13.93%)
5.39M
TRPTower Resources Plc
0.0395p
(5.33%)
539.51M
CPXCap-xx Limited
0.1825p
(1.39%)
494M
NTVONativo Resources Plc
0.0019p
(0.00%)
320.16M
DGIDg Innovate Plc
0.0225p
(-13.46%)
208.21M
ENETEthernity Networks Ltd
0.1125p
(2.27%)
207.56M

Discussion

View Full Feed
Mr. Bill Mr. Bill 7 minutes ago
https://www.medicinenet.com/what_are_blood_oxygen_levels/article.htm
devil dog 96 devil dog 96 9 minutes ago
Tell everyone why you think they never took the 39 million shares off restriction if they need shares to dump? Why have they not taken 1 share off restriction since early 2021 if they need shares to dump?? Why would they issue new shares that will be unregistered and also have to wait a year before
ATMH
CrossFireTrader CrossFireTrader 9 minutes ago
Page 22 of 26, and If say I'm Bullish that'll set 280e off, and I'll  be accused of pumping our little lottery ticket. I'm here for the long haul. I'm not here to sell at 0.016 or 0.02 or 0.03 or whatever his new price is. He actually likes GDVM a lot more than he lets on. Since you seem to be somew
GDVM
Mr. Bill Mr. Bill 13 minutes ago
https://measuringmyhealth.com/what-is-a-normal-pi-on-a-pulse-oximeter/
georgejjl georgejjl 13 minutes ago
That is WRONG. The current standard of care is donepezil (Aricept) and memantine, etc.

MAB's still are an extremely small number of treatments for Alzheimer's in the USA and worldwide.

Good luck and GOD bless,
AVXL
axelvento axelvento 33 minutes ago
Q1 the first interim analysis of the vaccine’s efficacy is expected

Moderna’s mRNA-1647
Cytomegalovirus
MRNA
MightyX MightyX 36 minutes ago
Yet no one is innocent
TPTW
BIG D 4 BIG D 4 37 minutes ago
WOW !! HAPPY NEW YEAR TO ALL THE LONGS HERE !! I HAVE 2 NAYSAYERS ON IGNORE SO I NEVER READ THEIR BS !! GO SAVING GRACE-- JJ AND ALL THE NEW POSTERS WHO ARE POSITIVE !! .02 CENTS TO START THE RUN TO ONE DOLLAR IS WHERE WE SHOULD BE !! THIS STOCK IS SUCH A GREAT BUY HERE !! I AM LOADED WITH 32 MILLI
MJNA
MightyX MightyX 37 minutes ago
The judicial system legitimizes prosecution
TPTW
jondoeuk jondoeuk 38 minutes ago
A new paper. From it: 'BNT221 was well tolerated across both DLs, with no dose-limiting toxicities of grade 3 or higher attributed to the T cell product observed. Specifically, no cytokine release, immune effector cell-associated neurotoxicity or macrophage activation syndromes were reported. A dose
BNTX
benz280c benz280c 39 minutes ago
Nice to see you are bullish. This quote may round out your knowledge.
"It is worthy to note that a new CUSIP has been approved by the CUSIP Global Services (CGS).
Subsequently, we have submitted a corporation action with FINRA for a Company name change, Ticker Symbol Change and Cusip
GDVM
shajandr shajandr 40 minutes ago
Sorry to read that you're still feeling sick. I posted a week or two ago about 41 bunnies and also some cats and dogs that were rescued from a home in Delaware county, Iowa and that were transferred to the DBQ county animal shelter. I just spoke with DaSqu_w and she went to the animal shelter to see
Lakota-45 Lakota-45 41 minutes ago
Will do, but I doubt they will listen !!!

~ Lol !!!
IONI
boi568 boi568 42 minutes ago
Probably
AVXL
HokieHead HokieHead 44 minutes ago
Wrong..
TWOH
HokieHead HokieHead 44 minutes ago
Get your facts straight, the halt was in the Canadian side as they are reviewing all the disclosures submitted, there’s ZERO issues in the US, it’s a fully reporting SEC company.
TWOH
Lakota-45 Lakota-45 46 minutes ago
I agree with you 'farmI1234 !!!

I'm pretty sure most of the Savvy Investors, that have been paying attention,
have been loading the dips, and .0004's, for a while now.
I know I have, along with fishing down stream.

I doubt any Longs will get caught short,
WDLF
CaptHowdy CaptHowdy 48 minutes ago
RECOMMENDED.... nothing is offical yet, unnecessary twisting of facts to bolster your negative viewpoints. Thats news is two months old
GRLT
axelvento axelvento 48 minutes ago
Cancer vaccines: What’s ahead in 2025

The spotlight is on mRNA-4157 (V940)

https://gulfnews.com/special-reports/cancer-vaccines-whats-ahead-in-2025-1.500010233
MRNA
facts_matter14 facts_matter14 49 minutes ago
Does this sound like a company with 16 products and a 17th on the way?

https://investorshub.advfn.com/uimage/uploads/2024/12/24/mwowsIMG_6034.png








.
SRMX
HomerRomer HomerRomer 49 minutes ago
More testimony videos from trial participants like the Australian news reel of Ern Heaven would be amazing. I would think that most of the people involved 9 years ago in the earlier phase studies have passed on since the average life expectancy is normally between 3-11 years after being diagnosed w
AVXL
CaptHowdy CaptHowdy 50 minutes ago
That's how to make money on the OTC. 🤦🏻‍♂️ Anyone could do it; only if the effort spent discounting the new leadership in place along with the turn around story underway was used to turn a profit vs. using 9yr old DD to bad mouth new CEO.
GRLT
crescentmotor crescentmotor 51 minutes ago
I think that is a bad precedent to start.

100% on parading a handful of Blarcamesine patients at the JPM conference. I highly doubt AVXL would involve itself with anecdotal gimmicks where there is no way possible to extrapolate isolated successes to meaningful conclusions about broad
AVXL JPM

Your Recent History

LSE
0RKT
Selvita
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads